The Zhitong Finance App learned that on Wednesday, Sarepta Therapeutics (SRPT.US) continued to drop nearly 20% and plummeted 40% over 2 trading days to $37.27. According to the news, the company reported a first-quarter non-GAAP (non-GAAP) loss of $3.42 per diluted share, compared with earnings of $0.72 per share for the same period last year. Analysts surveyed by FactSet expected a profit of $2.52. Revenue rose to $745 million from approximately $414 million in the same period last year, and analysts surveyed by FactSet estimated it at $688 million. The company lowered its 2025 net product revenue guidance to the $2.3 billion to $2.6 billion range.

The Zhitong Finance App learned that on Wednesday, Sarepta Therapeutics (SRPT.US) continued to drop nearly 20% and plummeted 40% over 2 trading days to $37.27. According to the news, the company reported a first-quarter non-GAAP (non-GAAP) loss of $3.42 per diluted share, compared with earnings of $0.72 per share for the same period last year. Analysts surveyed by FactSet expected a profit of $2.52. Revenue rose to $745 million from approximately $414 million in the same period last year, and analysts surveyed by FactSet estimated it at $688 million. The company lowered its 2025 net product revenue guidance to the $2.3 billion to $2.6 billion range.